Xeno-free autologous cultivated limbal epithelial transplantation is effective

Article

Using xeno-free autologous cultivated limbal epithelial transplantation has proven to be effective in restoring corneal epithelial stability and improving vision in patients with ocular surface burns

Using xeno-free autologous cultivated limbal epithelial transplantation has proven to be effective in restoring corneal epithelial stability and improving vision in patients with ocular surface burns, according to a paper published in British Journal of Ophthalmology.

Dr Virender S. Sangwan et al., L V Prasad Eye Institute, Kallam Anji Reddy Campus, India, conducted a retrospective study on 200 patients with unilateral total limbal cell deficiency caused by ocular surface burns. Patients were treated between 2001 and 2010 and underwent a small limbal biopsy from the normal eye.

For 10 to 14 days limbal epithelial cells were expanded ex vivo on the human amniotic membrane. This was completed by using a xeno-free explant culture system. The patient's affected eye received cultured epithelial monolayer and amniotic membrane substrate transplantation. The outcome measures included postoperative corneal surface stability, visual improvement and complications.

Of the 200 eyes studied, 142 presented with a fully epithelised, avascular and clinically stable corneal surface with a mean follow-up of 3±1.6 years. In 121 eyes a two-line improvement in visual acuity was found.

The investigation has demonstrated the success of the limbal epithelial transplantation in restoring corneal epithelial stability in patients with ocular burns.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.